Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable
hematological malignancy that affects the myeloid cell progenies and challenges patients of …

Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive …

Background Patients with acute myeloid leukaemia (AML) positive for internal tandem
duplication (ITD) mutations of FLT3 have poor outcomes. Quizartinib, an oral, highly potent …

PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT),
patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the …

Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and …

PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy
for relapsed/refractory FLT3-mutated (FLT3 mut) acute myeloid leukemia (AML) but seldom …

The implementation of targeted therapies for acute myeloid leukaemia (AML) has been
challenging because of the complex mutational patterns within and across patients as well …

Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin …

Myelodysplastic syndrome (MDS) is a clonal disease that arises from the expansion of
mutated haematopoietic stem cells. In a spectrum of myeloid disorders ranging from clonal …

Biallelic mutations of the CEBPA gene (CEBPA bi) define a distinct entity associated with
favorable prognosis; however, the role of monoallelic mutations (CEBPA sm) is poorly …